Veradermics, Inc. (MANE) intrinsic value & 10-year financials
Veradermics, Inc. (MANE) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $108.82
- Market cap
- $81.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 42.8%
- Free cash flow (FY2025)
- -$71.6M
MANE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$70.0M | -$111.91 | -$71.6M | — | 59.2% |
| FY2024 | — | -$26.5M | -$37.05 | — | — | 26.4% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Veradermics, Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Veradermics, Inc has earned high returns on invested capital, averaging 42.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Veradermics, Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Veradermics, Inc is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.